Infectious Disease · Topic 1 of 10

Empiric Antibiotics & Stewardship

Infectious disease · antimicrobial stewardship

Empiric Antibiotics & Stewardship

Culture first, treat fast and broad enough when sick, then de-escalate to the narrowest agent for the shortest effective course.

Key numbers

Septic shock: antibiotics within 1 hour≤ 1 h

Shortest effective course — often 5–7 days5–7 days

Vancomycin: dose to an AUC of 400–600AUC 400–600

01 · FirstSeptic shock: antibiotics within 1 hour

Give antimicrobials within 1 hour of recognizing possible septic shock or probable sepsis; for possible sepsis without shock, investigate rapidly and give them within 3 hours if infection is still suspected.

02 · DoDe-escalate when cultures return

Hold an antibiotic time-out once cultures and susceptibilities return: de-escalate to the narrowest effective agent, and stop empiric therapy if a noninfectious cause is shown or strongly suspected.

03 · The ruleShortest effective course — often 5–7 days

Use the shortest effective course: nonsevere CAP under 5 days (minimum 3) once stable, uncomplicated cellulitis 5 days, pyelonephritis 5–7 days, HAP/VAP 7 days, uncomplicated gram-negative bacteremia 7 days.

The rules

Know these

Culture first, then cover the likely organisms must knowObtain cultures (including blood cultures in sepsis) before the first dose when this causes no delay, then choose empiric therapy by infection site, severity, patient risk factors and local resistance patterns.

Cover MDR organisms only with risk factorsAdd empiric coverage for a specific MDR pathogen (MRSA, resistant gram-negatives) only with risk: prior colonization or infection with it, prolonged broad-spectrum antibiotics, or long stay in a unit where it is prevalent.

Do not treat asymptomatic bacteriuriaDo not screen for or treat asymptomatic bacteriuria or culture-positive colonization without infection — including in diabetes, older adults and chronic catheters; exceptions are pregnancy and certain invasive genitourinary procedures.

What it is

Core idea

Time-dependent vs concentration-dependent killingBeta-lactams kill by time above the MIC (favoring frequent or prolonged dosing); aminoglycosides, fluoroquinolones and daptomycin kill by peak concentration (favoring large once-daily doses); vancomycin activity tracks AUC/MIC.

Causes & risk factors

Why it happens

Limit the antibiotics that drive C. difficileStewardship programs should target the antibiotics most associated with C. difficile infection — clindamycin, fluoroquinolones and cephalosporins, especially third-generation — to lower CDI rates.

Diagnosis & monitoring

Work-up

Vancomycin: dose to an AUC of 400–600For serious MRSA infection, dose vancomycin by AUC (target 400–600 mg·h/L) rather than troughs; trough-guided dosing to 15–20 mg/L causes more nephrotoxicity.

Procalcitonin helps stop, not start, antibioticsDecide to start antibiotics in suspected sepsis on clinical evaluation alone; once source control is adequate and the right duration is unclear, use procalcitonin plus clinical evaluation to decide when to stop.

Do right now

In this order

First moves

Culture first, then cover the likely organisms

→

Septic shock: antibiotics within 1 hour≤ 1 h

→

De-escalate when cultures return

→

Shortest effective course — often 5–7 days5–7 days

Why each step

Culture first, then cover the likely organismsObtain cultures (including blood cultures in sepsis) before the first dose when this causes no delay, then choose empiric therapy by infection site, severity, patient risk factors and local resistance patterns.

Septic shock: antibiotics within 1 hourGive antimicrobials within 1 hour of recognizing possible septic shock or probable sepsis; for possible sepsis without shock, investigate rapidly and give them within 3 hours if infection is still suspected.

De-escalate when cultures returnHold an antibiotic time-out once cultures and susceptibilities return: de-escalate to the narrowest effective agent, and stop empiric therapy if a noninfectious cause is shown or strongly suspected.

Shortest effective course — often 5–7 daysUse the shortest effective course: nonsevere CAP under 5 days (minimum 3) once stable, uncomplicated cellulitis 5 days, pyelonephritis 5–7 days, HAP/VAP 7 days, uncomplicated gram-negative bacteremia 7 days.

Management

Orders

Prolonged beta-lactam infusions in sepsisIn sepsis or septic shock, give maintenance beta-lactam doses as prolonged infusions after an initial loading dose rather than as boluses; use therapeutic drug monitoring selectively.

Switch IV to oral when the patient improvesConvert IV to oral therapy once the patient is improving and can take and absorb oral drugs; IV remains preferred with vomiting, malabsorption or impaired gut function, or critical illness.

ESBL infections: a carbapenem, not piperacillin-tazobactamFor invasive ESBL-producing Enterobacterales infection outside the urinary tract, use a carbapenem (meropenem or imipenem if critically ill); piperacillin-tazobactam is not suggested even when the isolate tests susceptible.

Preauthorization or prospective audit and feedbackThe core stewardship interventions are preauthorization of selected agents and/or prospective audit and feedback to prescribers (strong recommendation, IDSA/SHEA 2016).

Empiric or definitive therapy?

Commonly confused

When	Before culture results, after cultures are drawn
Chosen by	Site, severity, MDR risk factors and local resistance
Spectrum	Broad enough for the likely pathogens; MDR coverage only with risk
Next step	Time-out and de-escalate

Commonly confused

Tell apart

Most reported penicillin allergies are not realAbout 10% of patients report penicillin allergy but fewer than 5% have true IgE- or T-cell–mediated allergy, and penicillin–cephalosporin cross-reactivity is about 2%; assess and delabel instead of defaulting to broad-spectrum alternatives.

More detail

Reference

Show 7 reference facts

KPC-producing CRE: ceftazidime-avibactam, meropenem-vaborbactam or imipenem-relebactam; NDM producers: aztreonam-avibactam or cefiderocol. Reserve these agents for carbapenem-resistant organisms, with ID input.

CDC's 7 Core Elements of hospital stewardship: leadership commitment, accountability, pharmacy expertise, action, tracking, reporting and education.

Low-risk penicillin allergy histories (GI upset, family history, remote unknown reaction) can go to direct amoxicillin challenge; moderate-risk histories get skin testing, whose negative predictive value exceeds 95%.

Abscesses and infections involving foreign bodies need drainage or removal; antibiotics alone usually fail without source control.

Rapid molecular diagnostics on positive blood cultures speed de-escalation only when paired with active stewardship review and interpretation.

Combine antibiotics for polymicrobial infection or synergy (a cell wall–active agent plus an aminoglycoside); in S. aureus bacteremia, routinely adding gentamicin or rifampin brings kidney injury without benefit.

Pharmacokinetic monitoring and dose-adjustment programs are recommended for aminoglycosides and suggested for vancomycin as stewardship interventions.

Pearl

Right drug, right dose, right route, right duration — and stop when the infection is not there.

Sources · Merck Manual Professional — Overview of Antibacterial Medications · SCCM — Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 (recommendation summary) · Barlam TF et al. Implementing an Antibiotic Stewardship Program: Guidelines by the IDSA and SHEA. Clin Infect Dis 2016;62:e51–e77 · Lee RA et al. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the ACP. Ann Intern Med 2021;174:822–827 (abstract via Europe PMC) · Jones BE et al. Diagnosis and Management of Community-acquired Pneumonia: An Official ATS Clinical Practice Guideline. Am J Respir Crit Care Med 2025 · BALANCE Investigators. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med 2025 · Kalil AC et al. Management of Adults With HAP and VAP: 2016 IDSA/ATS Clinical Practice Guidelines. Clin Infect Dis 2016;63:e61–e111 · Shenoy ES et al. Evaluation and Management of Penicillin Allergy: A Review. JAMA 2019;321:188–199 (abstract via Europe PMC) · Tong SYC et al. Management of Staphylococcus aureus Bacteremia: A Review. JAMA 2025 · IDSA 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections (published July 30, 2026) · CDC — Core Elements of Hospital Antibiotic Stewardship Programs (updated Sept 2025) · Merck Manual Professional — Bacterial Urinary Tract Infections (UTIs) · Trautner BW et al. IDSA 2025 Guideline on Complicated Urinary Tract Infections · Merck Manual Professional — Clostridioides difficile Infection · Rybak MJ et al. Therapeutic monitoring of vancomycin for serious MRSA infections: revised consensus guideline (ASHP/IDSA/PIDS/SIDP). Am J Health Syst Pharm 2020;77:835–864 (open copy at ashp.org) · Starter sheet built from the verified AGACNP fact map (facts reviewed 2026-10-15).